{"id":"NCT00319020","sponsor":"Actelion","briefTitle":"Bosentan in Children With Pulmonary Arterial Hypertension Extension Study","officialTitle":"An Open Label, Long-term, Safety, and Tolerability Extension Study Using the Pediatric Formulation of Bosentan in the Treatment of Children With Idiopathic or Familial Pulmonary Arterial Hypertension Who Completed FUTURE 1","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-08-23","primaryCompletion":"2011-10-28","completion":"2011-10-28","firstPosted":"2006-04-27","resultsPosted":"2017-03-29","lastUpdate":"2025-02-04"},"enrollment":33,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Arterial Hypertension"],"interventions":[{"type":"DRUG","name":"Bosentan","otherNames":["Ro 47-0203","Tracleer"]}],"arms":[{"label":"Bosentan","type":"EXPERIMENTAL"}],"summary":"The main objective of the FUTURE 2 study was to assess the long-term safety and tolerability of the pediatric formulation of bosentan in children with idiopathic pulmonary arterial hypertension or familial pulmonary arterial hypertension who completed FUTURE 1 study.","primaryOutcome":{"measure":"Change From Baseline to End of Study (EOS) in Height for Age.","timeFrame":"From baseline (FUTURE 1) up to 28 days after study treatment discontinuation (EOS or premature study treatment discontinuation), i.e. 32 months in average","effectByArm":[{"arm":"Patients With Previous Bosentan","deltaMin":-0.8,"sd":null},{"arm":"Bosentan-naive Patients","deltaMin":0.32,"sd":null},{"arm":"Total","deltaMin":-0.64,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["26386921"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":15},"commonTop":["NASOPHARYNGITIS","ABDOMINAL PAIN","BRONCHITIS","UPPER RESPIRATORY TRACT INFECTION","FLUSHING"]}}